Shares of Teva Pharmaceutical Industries (TEVA) rose more than 2% over the past week. The global pharmaceutical and drug company known from its drugs Copaxone and Azilect reported its third quarter results on Thursday.
Third Quarter Results
Teva Pharmaceuticals reported third quarter revenues of $4.97 billion, up 14% on the year. Revenues fell slightly short of analysts expectations of $5.07 billion.
Teva reported a GAAP net loss of $79 million, or $0.09 per diluted share. This compares to a profit of $916 million, or $1.03 per diluted share. Net losses were explained by two large charges which Teva took during the quarter.
Read the entire article on Seekingalpha by clicking the following link
No comments:
Post a Comment